The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed. 3-Hydroxy-1,2,3-benzotriazin-4(3H)-one (HODHBt) enhances...

Full description

Bibliographic Details
Main Authors: Dennis C. Copertino Jr., Carissa S. Holmberg, Jared Weiler, Adam R. Ward, J. Natalie Howard, Callie Levinger, Alina P.S. Pang, Michael J. Corley, Friederike Dündar, Paul Zumbo, Doron Betel, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Noemi Linden, Bernard J. Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Colin Kovacs, Erika Benko, Alberto Bosque, R. Brad Jones, for the AIDS Clinical Trials Group (ACTG) A5321 Team
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-09-01
Series:JCI Insight
Subjects:
AIDS/HIV
Immunology
Online Access:https://doi.org/10.1172/jci.insight.169028

Internet

https://doi.org/10.1172/jci.insight.169028

Similar Items